Pancreatic Cancer

Title Average Ratingsort ascending
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal 100.00%
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. 100.00%
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? 98.00%
An Integrated Cancer Treatment program. 97.50%
Ukrain (NSC-631570) in the treatment of pancreas cancer. 95.00%
Psorinum, the anti cancer miracle from India. 92.73%
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. 90.00%
A homeopathic approach to treat patients with advanced gallbladder, periampullary, and liver carcinomas: a report of 3 cases. 90.00%
Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. 90.00%
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. 90.00%
Opioid growth factor and the treatment of human pancreatic cancer: a review. 90.00%
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. 90.00%
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic ca 90.00%
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell 90.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. 90.00%
71 year old woman, Pancraetic cancer with liver and lung metastasis. 90.00%
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alp 90.00%
Clinical Investigations on Ukrain 90.00%
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category: 90.00%
GcMAF-The cancer revolution from Japan 87.33%
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial 85.00%
Effect of emodin combined gemcitabine on the growth and apoptosis of pancreatic cancer cell line BxPC-3 in vitro 80.00%
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. 80.00%
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from 80.00%
Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins 80.00%
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt 80.00%
Alternative Cancer Treatment (interview with Dr. Gonzalez by Dr. Mercola) 80.00%
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expressio 80.00%
Metformin in the treatment of Cancer 77.00%
Cancer Psychotherapy according to Dr. Frederick B Levenson 73.33%
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. 70.00%
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer 70.00%
Efficacy of ukrain in the treatment of pancreatic cancer. 70.00%
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer 70.00%
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. 70.00%
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. 70.00%
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. 70.00%
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses 70.00%
Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by Conventional Methods and Optical Imaging. 70.00%
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer 70.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. 70.00%
Survivin and pancreatic cancer. 60.00%
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. 60.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi 60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". 60.00%
Tissue factor, angiogenesis and thrombosis in pancreatic cancer. 60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo 60.00%
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. 60.00%
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. 55.00%
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? 50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca.. 40.00%
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. 40.00%
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic 40.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 40.00%
Serum cytokines in pancreatic cancer: Correlation with outcome 40.00%
Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment 30.00%
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. 30.00%
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. 20.00%
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carci 0.00%